搜索
 > 【IGF-II】重组蛋白信息

IGF-II信息

英文名称:Insulin-like growth factor II
中文名称:胰岛素样生长因子Ⅱ
靶点别称:Insulin-like growth factor II,Preptin,T3M-11-derived growth factor,IGF2,IGF-II,Insulin-like growth factor II Ala-25 Del,Somatomedin-A
上市药物数量:0
临床药物数量:2
最高研发阶段:临床二期

IGF-II产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
IG2-H82F9
Human
Biotinylated Human IGF-II, Fc Tag, Avi Tag (Avitag?)
IG2-H4260
Human
Recombinant Human IGF-II / C11orf43 Protein

IGF-II 分子别名

IGF2,C11orf43,FLJ22066,FLJ44734,IGF-II,PP9974

IGF-II 分子背景

Insulin-like growth factor 2 (IGF-2) is also known as Somatomedin-A, IGF-II, PP9974, and is one of three protein hormones that share structural similarity to insulin. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist; that is, to prevent IGF2 responses. The major role of IGF2 is as a growth promoting hormone during gestation. In the process of Folliculogenesis, IGF2 is created by Theca cells to act in an autocrine manner on the theca cells themselves, and in a paracrine manner on Granulosa cells in the ovary. IGF2 promotes granulosa cell proliferation during the follicular phase of the menstrual cycle, acting alongside Follicle Stimulating Hormone (FSH). After ovulation has occurred, IGF-2 promotes progesterone secretion during the luteal phase of the menstrual cycle together with Luteinizing Hormone (LH). Thus, IGF2 acts as a Co-hormone together with both FSH and LH. IGF-2 may play a key role in memory and could potentially be used to treat Alzheimer's Disease. It is sometimes produced in excess in islet cell tumours, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. has been shown to interact with IGFBP3 and Transferrin.

IGF-II 参考文献

IGF-II临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Xentuzumab BI-836845 临床二期 勃林格殷格翰 非小细胞肺癌, 前列腺癌, 乳腺癌, 实体瘤 详情
Dusigitumab MEDI-573 临床二期 MedImmune 乳腺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定